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ABSTRACT
Equine Gastric Ulcer Syndrome affects roughly 90% of performance horses. The
only reliable antemortem diagnostic method is endoscopy, which is an invasive process.
The cornerstone of treatment is acid suppression, a cost-prohibitive option that is not
viable for long-term use. The objectives of this study were to investigate the efficacy of a
polysaccharide (PS) supplement on gastric ulcers in the squamous (SQ) and glandular
(GL) regions of the equine stomach and identify associated serum and salivary
biomarkers. It was hypothesized that severity of SQ and GL ulcers throughout the
supplemental period would decrease and levels of serum and salivary proteins, as well as
total antioxidant capacity (TAC), would fluctuate with ulcer scores. To test this
hypothesis, 8 mature geldings were randomly assigned to a PS-supplemented (TRT) or
non-supplemented (CTRL) group once they underwent ulcer induction using a modified
Murray method: alternating 12- and 24-hr feed deprivations for a total of 108hr.
Following the induction, TRT horses’ feed was top-dressed with 1oz of PS supplement
twice daily. Horses were fed 1.0% BW in Fescue hay (Festuca pratensis) and 0.25% BW
in concentrates daily (Nutrena® Triumph® Fiber Plus, Cargill®, Inc., Holmesville, OH)
with ad libitum water access, as recommended by the NRC. Horses were housed in
3.05x3.65m stalls and 4 were turned out per 0.809ha pastures from 0600-1800hrs and
1800 to 0600hrs, respectively. Pastures were composed of Fescue (Festuca pratensis),
rye (Lolium multiflorum), clover, and other native grasses. The experiment was divided
into 3 periods: pre- (Day 0), mid- (Day 28), and post-supplementation (Day 42). Per
period, endoscopic images were captured and saliva, blood, and gastric fluid samples
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were collected. The effects of time and treatment were analyzed with a factorial
ANOVA. All statistical calculations were performed using the software JMP. The
severity of ulcer scores decreased in all horses over the 6-week timespan (P=0.001), with
no difference found in ulcer scores between TRT and CTRL horses in the SQ or GL
regions. It is possible that the body’s innate healing capacity was adequate in this study,
which may have masked the treatment effect of the PS supplement. There was a
correlation found between salivary TAC (R2=0.559; P=0.005) and serum TAC
(R2=0.620; P=0.002) and ulcer score, which may indicate a shift in oxidative stress
factors as ulcers heal. The investigation of polysaccharide supplementation as a
preventative measure in ulcerative and non-ulcerative horses under stress is warranted.
Additionally, the exploration of other salivary and serum biomarkers to further develop a
panel for preliminary screening of equine gastric ulcers should be pursued.
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CHAPTER ONE
LITERATURE REVIEW
Terminology
The term Equine Gastric Ulcer Syndrome (EGUS) was first used in 1999 to
describe gastric ulceration in the horse (Andrews, 1999). Termed by the Equine Gastric
Ulcer Council (EGUC), EGUS is defined as the disease complex that is associated with
ulceration of the esophageal, gastric, or duodenal mucosa. Misuse of this term is common
and the EGUC emphasized the importance of distinguishing between diseases of the
squamous (SQ) and glandular (GL) mucosa, as their pathophysiology and treatment
needs differ greatly (Merritt, 2009). Thus, the term EGUS is used as an all-encompassing
term to describe ulcerative and erosive diseases of the equine stomach, Equine Squamous
Gastric Disease (ESGD) describes ulcerations of the SQ mucosa, and Equine Glandular
Gastric Disease (EGGD) describes ulcerations of the GL mucosa. ESGD can be further
categorized as primary, the more common form, or secondary. Animals diagnosed with
primary ESGD have an otherwise normal gastrointestinal (GI) tract and those diagnosed
with secondary ESGD have an underlying gastric abnormality. Specifications of EGGD
are lacking, thus it is recommended to diagnose ulcerations according to their anatomical
location (cardia, fundus, antrum, or pylorus) and the appearance of the lesion (Sykes et
al., 2015a).
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Pathophysiology
Squamous mucosa
The degree that stratified SQ mucosa extends from the esophagus into the
stomach varies between domestic species. In horses, it is the proximal one half of the
stomach, which is histologically composed of 4 major zones: stratum corneum, stratum
transitionale, stratum spinosum, and stratum basale. No mucus cells are present within
these layers. The main function of the metabolically active layers below the stratum
corneum is active Na+ transport, operated by Na+-K+ATPases (Chien and Stevens, 1972).
The SQ mucosa’s high electrical resistance aids in barrier function, prohibiting
penetration by large molecules. There is a minimal barrier of tight junctions present in the
stratum corneum, which is supported further by the principal barrier of the stratum
spinosum. Once past the latter barrier, there is minimal resistance to the penetration of
large molecules (Orlando, 1991). Weak acids, such as short chain fatty acids (SCFA) that
result from microbial digestion of carbohydrates, are also considered weak electrolytes.
This allows their rapid diffusion across the mucosal barrier as luminal pH decreases,
which in swine has been found to irreversibly insult the current of Na+ transport that
results in a decrease in electrical resistance, thus indicating the reduction of barrier
function. The process of injury to SQ mucosa via SCFA progresses from penetration of
the outer barrier, acidification of the underlying transport cells, elimination of the short
circuit current, cell swelling, to a fall in electrical resistance. Contrarily, injury from a
strong acid, such as HCl, results in erosion of outer layers of the mucosa, acidification of

2

transporting cells via exposure to H+, diminished cell volume regulation, cell swelling,
and eventual necrosis (Argenzio, 1999; Carney et al., 1981).
Glandular mucosa
The pathophysiology of EGGD is less understood, as the mucosa of the GL region
functions differently than the SQ mucosa. The GL mucosa consists of a mucusbicarbonate layer on the epithelium surface, which is responsible for titrating incoming
luminal H+ ions to CO2 and H2O (Flemstrong, 1994). Unlike SQ mucosa, GL mucosa has
varying capacity to heal by migration of healthy tissue to the site of injured tissue, a
process denoted as restitution (Silen, 1987). Another difference between the mucosa is
the protective properties of prostaglandins for the GL region, which aid in increased
blood flow as well as mucus and bicarbonate secretion (Orlando, 1991). Under normal
physiological health, the GL mucosa is constantly exposed to acidic pH levels (1-3) and
has the capacity to function in this condition. Thus, EGGD occurs when the natural
barriers of the GL mucosa are broken down and defense mechanisms fail. These
mechanisms that contribute to the breakdown have not been elucidated in the horse and
are of interest (Merritt et al., 2003).
The role of bacteria in EGGD is controversial. It is unknown whether gastric
bacteria and pathogens play a role in GL ulceration as they do in the SQ region. In some
studies, horses affected by EGGD had the presence of Helicobacter-like organisms
(Contreras et al., 2007; Fox, 2002), where in others there was failure of identification
(Husted et al., 2010; Martineau et al., 2009).
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The role of non-steroidal anti-inflammatory drugs’ (NSAIDs) cause in EGGD is
also controversial. At doses 50% higher than recommended flunixin, phenylbutazone,
and ketoprofen have proven to have ulcerogenic capacity (Cg et al., 1993). However,
when administered at clinical doses for 15 days, phenylbutazone and suxibuzone did not
induce gastric ulcers (Andrews et al., 2009).
Prevalence
The prevalence of gastric ulceration varies with breed, use, level of training, as
well as between ESGD and EGGD (Andrews et al., 2009). Thoroughbreds represent the
highest portion of horses diagnosed with ESGD, affecting 37% of untrained and 80-100%
of those who undergo race training for 2-3 months (Begg and O’Sullivan, 2003; Murray
et al., 1996; Vatistas et al., 2010). Similarly, the percentage of ESGD increases from 44%
in non-training to 87% with training in Standardbred horses (Dionne et al., 2003; Jonsson
and Egenvall, 2006; Rabuffo et al., 2002). Additionally, around 17-58% of show/sport
horses and 37-59% of pleasure horses are affected (Hartmann and Frankeny, 2003;
Luthersson et al., 2009a; McClure et al., 1999; Murray et al., 1989; Niedźwiedź et al.,
2013). Outside of competition season, around 48% of endurance horses have been found
to be affected by ESGD, while 66-93% of those in the midst of competition season are
affected, with a higher rate in the elite horses (Nieto et al., 2004; Tamzali, 2011). Horses
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that do not commonly travel or compete have an 11% prevalence of ESGD (Chameroy et
al., 2006).
Research on the prevalence of EGGD is not as thorough. Prevalences between
47% and 65% have been reported in Australian Thoroughbred horses and between 16%
of non-competitive endurance horses and 27-33% of competitive endurance horses (Begg
and O’Sullivan, 2003; Nieto et al., 2004; Sykes et al., 2015b; Tamzali, 2011). In the
United Kingdom, a reflective study found 54% of 191 leisure horses and 64% of 493
sport horses had EGGD (Hepburn, 2005). Similarly, in 2 separate studies, 57% of horses
used for a variety of purposes were reported to have EGGD (Husted et al., 2010;
Luthersson et al., 2009a). For each of the previously mentioned studies involving EGGD,
the majority of lesions were found in the pyloric antrum.
Risk Factors
Nutrition
There is conflicting evidence surrounding the capability of pasture turnout to
reduce the risk of EGUS. While grazing, the horse’s continuous secretion of saliva and
influx of ingesta act to buffer stomach acid. When feed access is intermittent, gastric pH
drops, exposing the SQ mucosa to an acidic environment (Buchanan and Andrews,
2004). One particular study involving Thoroughbred horses in training found that horses
in turnout were less likely to have ESGD, and those turned out with the company of other
horses had an even lower risk (Lester et al., 2007). On the contrary, a separate study on
Thoroughbred horses in training found no effect of quality of pasture or time at pasture
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on ESGD risk (Bell et al., 2007). An additional study’s findings suggested that pasture
turnout on its own might not affect gastric pH. This was based on a lack of intragastric
pH difference in horses fed ad libitum grass hay and grain twice per day (1 kg/100 kg/d)
when they were housed in a grass paddock, in a stall on their own, or in a stall with an
adjacent companion (Husted et al., 2008).
Free access to fibrous feed or frequent forage feeding is widely considered to
reduce the risk of gastric ulceration (Sykes et al., 2015a). At a minimum, those receiving
hay should be offered 1.5% of their bodyweight per day (Videla and Andrews, 2009).
Horses and ponies that are overweight and at risk of EGUS should be offered hay that is
mature with a low energy content. If there is no low-energy hay available, a mixture of
high-quality hay and straw can be offered, but straw should not be the only forage
provided, as it is suggested that forage type is an important factor in the prevention and
management of EGUS. When attempting to raise gastric pH and decrease peptic injury, a
diet consisting of alfalfa hay and grain was found to be more effective than a diet absent
of grain and consisting solely of brome grass hay or coastal Bermuda hay (Lybbert et al.,
2007; Nadeau et al., 2000). Adding to that suggestion, there is an increased likelihood of
ESGD when straw is the sole forage provided (Luthersson et al., 2009a). In addition, the
impact of forage feeding in the absence of alternate risk factor reduction might not be as
effective as previously thought. In one study, both the number and severity of ESGD
lesions were greater in the high-fiber group in comparison with the group fed an isoenergetic diet (Boswinkel et al., 2007). It has also been found that the likelihood of
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ESGD is increased when time intervals between forage meals increases (Luthersson et
al., 2009a).
Consistently, it has been found that there is an increased risk of ESGD in animals
working at various levels of intensity that have an increased starch/grain intake. When
non-exercising horses are stabled and fed grain at 1% of BW one hour before hay is
given, there is a notable increase in ulceration (Frank et al., 2005). Furthermore, there is
an approximately two-fold increased risk of ESGD in horses fed amounts exceeding
2g/kg BW of starch intake per day (Luthersson et al., 2009a). Horses maintaining a 6
kg/d diet of grain that entered an artificial training regimen and stabling after being
removed from pasture developed ESGD within 14 days (Vatistas et al., 1999). High
concentrate diets are typically high in non-structural carbohydrate, such as starch. In the
process of starch digestion by fermentation via residential bacteria, VFAs are produced.
The presence of VFAs in a stomach with a pH ≤4 directly causes acid damage to SQ
mucosa (Nadeau et al., 2003). Diets higher in protein and calcium (alfalfa hay/grain) have
resulted in less severe gastric ulcers when compared to a low protein and calcium diet
(brome grass hay), indicating a potential protective effect of alfalfa hay on the SQ
mucosa (Buchanan and Andrews, 2004).
Another factor increasing a horse’s risk of developing EGUS is intermittent
access to water. It has been shown that horses without water access are over 2.5 times
more likely to have EGUS than those with ad libitum water access (Luthersson et al.,

7

2009a). Interestingly, this risk factor applied to all portions of the stomach, as opposed to
solely affecting the SQ mucosa.
Exercise
The relationship between training or racing and prevalence is significant, as
approximately 60-90% of performance horses suffer from EGUS (Buchanan and
Andrews, 2004). When the horse is at a gait faster than a walk, the increased intraabdominal pressure and decreased stomach volume causes acidic gastric contents to push
up to the level of the SQ mucosa, resulting in prolonged exposure of the mucosa to acidic
gastric contents (Lorenzo-Figueras and Merritt, 2002). Daily exercise may contribute to
increased exposure of the SQ tissue to acidic gastric contents, explaining the increased
prevalence of gastric ulcers in horses in training (Buchanan and Andrews, 2004).
Additionally, significant association has been found between increased interval training
for long durations and increased prevalence of lesions, lesion severity, and number of
lesion sites (Murray et al., 1996; Orsini et al., 2009; Roy et al., 2005). In elite endurance
horses, there is a direct correlation between distance of ride and severity of ESGD
(Tamzali, 2011).
Transportation
The increased incidence of EGUS in horses that are regularly transported is likely
due to decreased access to feed and water. Additionally, transportation is associated with
dehydration and immune suppression, potentially contributing to overall health decrease
(Watson, 2002).
Stall confinement
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The influence of stall confinement on the development of gastric ulcers is likely
multifactorial, as intermittent feeding and restriction of exposure to other horses are
common in those that are housed in stalls. However, one study did find that horses
housed in pastures have a decreased prevalence when compared to horses confined to
stalls (Fiege et al., 2002).
Nonsteroidal anti-inflammatory drugs
It has been proven that various NSAIDs cause gastric ulcers in horses (MacAlliser
and Sangiah, 1993). Abundant studies in Thoroughbred racehorses have contradicted this,
each coming to the conclusion that the use of NSAIDs in racehorses is not a risk factor
for EGUS (Johnson et al., 1994; McClure et al., 1999; Murray et al., 1996; Rabuffo et al.,
2002; Vatistas et al., 2010). However, another study found that NSAIDs did cause ulcers
of the GL mucosa and increased the severity of ulcers of the SQ mucosa (MacAlliser et
al., 1992). NSAIDs are thought to have a greater negative impact on GL mucosa due to
their role in prostaglandin inhibition, which results in decreased mucosal blood flow,
decreased mucus production, and increased HCl secretion. The regulation of acid
production, Na+ transport, and mucosal blood flow by prostaglandins is crucial to GL
mucosal integrity, with adequate blood flow likely being the most influential. Its aid in
the removal of diffused H+ ions through the mucus layer is critical (Barr, 2001; Murray,
1991).
Helicobacter spp
There are controversial findings concerning the influence of Helicobacter pylori
on the development of gastric ulcers in horses. One study was able to isolate H. pylori
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DNA from both the SQ and GL mucosa of seven horses with ulcers, while other
postmortem reports of horses with and without EGUS lacked any presence of related
organisms (Johnson et al., 1994; Scott et al., 2001). Nevertheless, adjunctive therapies
along with acid suppression may be beneficial for the treatment of gastric ulcers in
horses, as it is such in other species.
Clinical Signs
Individual cases of EGUS often present with a large range of vague clinical signs.
The most seen at the population level is reduced appetite and poor body condition. It is
common that behavioral inconsistencies such as nervousness, aggression, and selfmutilation occur alongside ulcer presence. Considering the numerous factors that play a
role, it is fair to say EGUS might result in reduced performance, but other components
should also be addressed. It is not advisable to diagnose EGUS via clinical signs, but to
definitively diagnose the syndrome via endoscopy (Scott et al., 2001).
Colic
There is evidence suggesting that gastric ulcers are associated with an increased
likelihood of colic and postprandial abdominal upset (Murray, 1992; Murray et al., 1989;
Sandin et al., 2000; Vatistas et al., 2010; Videla and Andrews, 2009). In one study, it was
reported that 83% of horses with recurrent colic had gastric ulcers after undergoing
suppressive acid treatment (Murray, 1992). Additionally, a study found that 3.5% of
horses that exhibited colic in the preceding month had ESGD and another reported that
49% of horses presenting acute colic had ESGD (Vatistas et al., 2010). In the latter study,
it was also seen that colicking horses that were medically managed had a higher rate of
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ESGD in comparison to those that underwent surgical management (Dukti et al., 2006).
Though uncertain, the difference in rates of ESGD between the two groups might be
attributable to medically-managed horses undergoing longer periods of fasting
(Berschneider et al., 1999; Murray, 1996).
Poor coat condition
Results concerning an association between poor hair coat and gastric ulceration
are contradicting. There have been studies that found statistical association between the
two, while there have also been studies that failed to identify an association (Dionne et
al., 2003; le Jeune et al., 2009; Vatistas et al., 2010).
Diarrhea
There is no definitive cause-and-effect relationship between diarrhea and gastric
ulceration, though it has been reported as a clinical sign in adult horses (Murray et al.,
1989). Moreover, it is likely that when there is an association between diarrhea and
gastric ulceration, there is a wider disease process occurring (Sykes et al., 2015a).
Stereotypical behaviors
Commonly, horses demonstrating altered or stereotypic behavior are likely to
present gastric ulcerations (Andrews and Nadeau, 1999; Murray et al., 1989). For
instance, competition horses with a nervous disposition tend to present ESGD more often
than quiet, normally-behaved horses (McClure et al., 1999). In addition to nervousness,
behavioral changes may include aggression and self-mutilation, which are behaviors such
as biting, stomping, and kicking (McDonnell, 2008). Some data from racehorses has
shown contrary results concerning a relationship between nervousness and ESGD, but
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interestingly showed correlation between aggression and ESGD (Lester et al., 2007).
Additionally, there is a correlation between cribbing and ESGD, though the biological
mechanism behind it is uncertain (Nicol et al., 2002).
Decreased performance
While poor performance is one of the most influential signs of ESGD, its
investigation is lacking. The particular question is if gastric ulcers directly cause poor
performance, rather than indirectly due to other clinical signs such as reduced appetite or
weight loss. It is most likely that reduced performance is linked to gastric pain (Andrews,
2008). Ulcerations of the SQ mucosa in horses are similar to lesions that cause heartburn
or gastroesophageal reflux disease (GERD) in humans. In one study it was found that
58% of elite athletes suffering from GERD reported upper GI pain during exercise, with a
proportional increase with intensity (Lj and Df, 1985). Additionally, human runners with
GERD experience decreased time to exhaustion when compared to runners without the
disease (Rodriguez-Stanley, 2006).
In racehorses, there has been limited research to provide an association between
performance and the presence of ulcers. Performance measurements vary from trainer
observation to objective physiologic responses through treadmill testing. It has been
found that, independent of the quantity and severity, there is an association between poor
performance and ESGD (Vatistas et al., 2010). Similar results have been found
concerning Standardbred racehorses, showing an association between ESGD presence
and reduced performance (Jonsson and Egenvall, 2006). A small trial consisting of 4
Thoroughbred horses that presented with gastric ulcers as the only abnormal factor found

12

that there was improved performance with omeprazole treatment (Franklin et al., 2008).
Within poor performance, it is postulated that abdominal pain caused by gastric ulcers
might affect stride length and ventilation. Intermittent feed deprivation was applied to a
population of horses in order to induce gastric ulcers, followed by half of the study
population receiving omeprazole treatment and half receiving no treatment. With
incremental treadmill exercise testing, physiological responses were recorded, and it was
found that treatment horses had increased time to fatigue and longer stride length when
compared to untreated horses (Nieto et al., 2009).
Diagnostics
Endoscopy is the only reliable antemortem method of diagnosing EGUS.
Preparation for endoscopy includes feed and water restrictions, as well as sedation. If
necessary, before alterations to the gastric environment are made, stomach fluid samples
are collected via aspiration. During the endoscopic procedure, the stomach is distended
by the insufflation of air through the endoscopy biopsy channel until the SQ and GL
regions of the gastric mucosa are visible. Gastric contents are thoroughly rinsed from the
stomach surface using tap water flushed through the biopsy channel. Throughout the
endoscopy, images are captured and digitized with a portable personal computer. At the
conclusion of this procedure, the endoscope is withdrawn, and horses are appropriately
recovered from sedation. When performing endoscopy, visualization of the entire
stomach is crucial as the presence or absence of ESGD or EGGD cannot be used to
predict the incidence of the other.
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Currently, there are no definitive hematological or biochemical markers found to
reliably aid in the diagnosis of EGUS. Though the diagnostic accuracy is not clinically
reported, sucrose permeability shows promise for a noninvasive diagnostic method of
gastric ulcers (Hewetson et al., 2006; O’Conner et al., 2004). There have been attempts to
correlate gastric ulcer presence with fecal albumin or hemoglobin, however no significant
association has been found (Pellegrini, 2005; Sykes et al., n.d.).
Ulcer Grading
After ulcer presence is identified by endoscopy, severity of the lesions must be
assessed. There are several methods of assigning ulcer grades, the most common being
one that describes the mucosal appearance as well as anatomical location. Grading scales
range from 0-3 to 0-10 in various publications (Andrews et al., 1999; Murray et al.,
1996). The EGUC recommends utilizing the existing 0-4 scoring system to be used for
ESGD and EGGD in order to provide clinical and research uniformity. The importance of
stating the anatomical location, distribution, and appearance of lesions in the GL portion
of the stomach has been emphasized, as the use of a definitive grading scale is
controversial. Thus, the grading of the ulcers initially indicates whether the horses have
ESGD or EGGD. Following this, lesion scores are assigned and range from 0-4 for each
of the ulcer types. For ESGD, 0 indicates the epithelium is intact and there is no
appearance of hyperkeratosis, 1 indicates the mucosa is intact but there are areas of
hyperkeratosis, 2 indicates small, single, or multifocal (<5) superficial lesions, 3 indicates
large single deep, or multiple (³5) focal superficial lesions, and 4 indicates extensive
lesions with areas of apparent deep ulceration. For EGGD, 0 indicates the epithelium is
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intact and there is no evidence of hyperemia, 1 indicates the mucosa is intact but there are
areas of hyperemia, 2 indicates small, single, or multifocal (<5) superficial lesions, 3
indicates large single deep or multiple (³5) focal superficial lesions, and 4 indicates
extensive lesions with areas of apparent deep ulceration (Sykes and Jokisalo, 2014, p. 1).
Treatment and Prevention
Commonly, empiric treatment is administered when endoscopy is unavailable.
Due to cost and importance of distinguishing between ESGD and EGGD, treatment
without definitive diagnosis is not recommended. However, if treatment is administered
empirically and there is a failure to respond, endoscopy should still be performed to rule
out gastric disease.
Pharmaceutical Therapy
Antacids
Antacids are mainly effective through neutralizing stomach HCl, but aluminumcontaining formulas have potential for added mucosal protective effects through the
stimulation of prostaglandin production. There are mixed conclusions on their efficacy of
controlling stomach pH (Szelnenyi et al., 1989). Varying compositions and
administrations of aluminum hydroxide and magnesium hydroxide were found to have
short-term effects on stomach pH (Clark et al., 1996; Murray and Grodinsky, 1992). It
has been gathered that efficacy of antacid administration seems dependent on frequent,
large doses, which may impact electrolyte absorption. There is slight symptomatic relief
from antacids, but the longevity of their efficacy is poor. The effects last £2 hours,
therefore its use as a sole therapeutic agent is unjustified (Clark et al., 1996; Murray and
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Grodinsky, 1992). Thus, administering antacids may be beneficial for relieving clinical
signs of EGUS, but are not likely effective in healing gastric ulcers (Buchanan and
Andrews, 2004).
Histamine type 2 receptor antagonists
Acid secretion from parietal cells is stimulated by histamine. Histamine type 2
(H2) receptor antagonists bind to the histamine receptor, thus decreasing acid secretion by
blocking histamine from attaching. The H2 receptor antagonist may also be proficient in
inhibiting gastric acid secretions caused by gastrin and acetylcholine (Brunton, 2000).
Cimetidine and ranitidine are the most reviewed H2 receptor antagonists. Cimetidine is
not extremely effective and ranitidine is more commonly used, as it is four times more
potent (Ross et al., 1981). Efficacy of ranitidine is dose-dependent, and in certain cases
may suppress acid output and maintain a stomach pH of 4.6 (Holland et al., 1997;
Johnson et al., 2001; Murray and Schusser, 1993).
Proton pump inhibitors
Currently, the cornerstone of gastric ulcer treatment is acid suppression in both
ESGD and EGGD. Omeprazole is the most well-reviewed proton pump inhibitor used for
the treatment of gastric ulcers in horses. It works by impairing the H+-K+ATPase pump
that secretes HCl (Clark et al., 1996). Currently, omeprazole it is the only FDA-approved
drug for EGUS treatment and is usually the drug of choice. It is effective only when
formulated to withstand the acidic environment of the stomach to avoid premature
degradation. Common methods of obtaining this formula include a buffered paste or
enteric coated granules, with contrasting evidence on which is superior (Birkmann et al.,
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2014). Overall, findings suggest that doses of omeprazole, either buffered or enteric
coated, are efficacious and warrant consideration.
When introduced to an acidic environment, omeprazole is activated to a
sulfonamide derivative and subsequently binds reversibly to H+-K+ATPase in parietal
cells. This results in the inhibition of H+ ion transport into the cell, hence its classification
as a proton pump inhibitor (Plumb, 2002). Omeprazole is metabolized in the liver and
excreted in the urine and bile, therefore horses with significant liver disease may
metabolize the drug at different rates. In other species, long-term administration has not
caused clinical, hematologic, or biochemical alterations, however, it has caused a
reversible gastric mucosal hypertrophy (Sundell and Nillsson, 1986), hyperplasia of
enterochromaffin-like (ECL) cells, and gastric carcinoid tumors (Tielemans et al., 1989).
In horses, no significant side effects have been reported when treated for up to 90 days.
The required duration of acid suppression to allow for healing of ESGD and
EGGD has not been defined in horses. Previous literature suggests that once daily
administration of omeprazole results in 24 hours of acid suppression, but recent studies
have countered this belief with finding acid suppression as short as 12 hours in some
animals (Daurio et al., 1999; Jenkins et al., 1992). Even so, based on several studies, 12hour acid suppression is sufficient for ESGD treatment. Another consideration to be
made is the duration of treatment. The standard omeprazole treatment is 28 days, but it
has been found that healing of ESGD has occurred in 21 days (Murray et al., 1997). Even
within the standard 28-day treatment, it is important to note that only approximately 7080% of ESGD lesions will heal (Andrews et al., 1999; Doucet et al., 2003; Murray et al.,
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1997). Thus, follow-up endoscopies must be continued until treatment has ceased to
ensure proper healing has occurred.
Treatments pertaining specifically to EGGD have not been considered until
recently. The difference in the healing process of the SQ and GL tissue warrant treatment
investigation. In a recent study where 28-35 days of omeprazole treatment was
administered, only 25% of EGGD lesions healed whereas ESGD lesions had a 78%
healing rate (B. W. Sykes et al., 2014a, 2014b; Sykes et al., 2015b). It is possible that
EGGD lesions might require longer treatment periods. In humans, the duration of
treatment for GL ulcerations depends on the cause of the injury, but is typically 8 and 12
weeks for 84% and 100% healing rates for ulcers induced by NSAIDs (Lancaster-Smith
et al., 1991). Healing rates of EGGD have been observed to be around the same time
frame; however, clinical trials tailored to this topic are lacking (Sykes et al., 2015a). In
addition to the possibility of longer treatment duration requirements, the role of bacteria
in EGGD should be examined. If bacteria play a factor in the development of EGGD,
omeprazole monotherapy might be inadequate, and the use of adjunctive therapies should
be considered. In humans, ulcerations associated with H. pylori call for triple treatment,
including antimicrobials. This results in healing rates >80% (Malfertheiner et al., 2009).
Theorizing from this, antimicrobial treatment in the horse for EGGD is popular.
However, antimicrobials do not improve healing of non H. pylori ulcerations in humans,
therefore no evidence exists to support their use in horses for healing EGGD
(Malfertheiner et al., 2009; Sykes et al., 2014).
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Coating or binding agents
The use of mucosal protectants for the treatment of EGGD is warranted given the
suggested role of mucosal defense failure in the development of GL lesions. The mucosal
protectant backed by the most research is sucralfate, which functions by adhering to
ulcerated mucosa as well as stimulating mucus secretion, prostaglandin E2 synthesis, and
blood flow, all of which are beneficial to the healing process of EGGD (Murray, 2017).
The hydroxyl aluminum salt of sucrose octasulfate becomes adhered due to the negative
charge of the ulcer bed, resulting in the secretion of bicarbonate that buffers HCl (Borne
and MacAllister, 1993). Additionally, once in the stomach, sucralfate is converted to a
sticky amorphous mass that may aid in the inhibition of H+ diffusion into the ulcer. The
efficacy of sucralfate alone is extremely variable. In combination with omeprazole
treatment, it has resulted in healing rates of 67.5% in the pyloric antrum, which is one of
the most common and resistant areas of ulceration in the GL region of the stomach
(Hepburn and Proudman, 2014).
Antibiotics
In humans, ulcerations associated with H. pylori call for triple treatment including
antimicrobials. This results in healing rates >80% (Malfertheiner et al., 2009).
Combination therapy has been most effective in other species, pairing acid suppressive
therapy with antibiotics (Hall, 2000). Theorizing from this, antimicrobial treatment in the
horse for EGGD is popular. However, antimicrobials do not improve healing of non H.
pylori ulcerations in humans, therefore no evidence exists to support their use in horses
for healing EGGD (Malfertheiner et al., 2009; Sykes et al., 2014).
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Nutraceutical Therapy
Pectin-lecithin complex
The ease of use and availability of nutraceuticals are appealing, but they provide
mixed results. Increased total mucus concentration in gastric juice has been found in
studies investigating pectin-lecithin complexes (Koeller, 2010). Contradicting this, two
studies involving pectin-lecithin complexes did not find a protective effect in horses with
ESGD (Venner et al., 1999). More recently, showing promise for treatment of ESGD and
EGGD simultaneously is a combination of an antacid (magnesium hydroxide), a pectinlecithin complex, and Saccharomyces cerevisiae (Sykes et al., 2014).
B vitamin complex
There has been promise of ESGD management by a feed supplement consisting of
B vitamins combined with organic salts as well as possible EGGD prevention via sea
buckthorn berries (Hellings and Larsen, 2014; Huff et al., 2012).
Corn oil
Arachidonic acid precursors, such as linoleic acid, have been investigated for their
ability to increase endogenous prostaglandin production and decrease maximally
stimulated acid output (Grant et al., 1988; Mandel et al., 1994; Schepp et al., 1988).
There is interest in the potential role of prostaglandins, specifically those of the E series,
to provide mucosal protection and potential therapeutic value as they have been found to
have anti-ulcer properties (Lanza, 1989; Wilson, 1988). In studies involving humans and
rats, it has been found that dietary supplementation with linoleic acid increased the
prostaglandin E2 concentration in gastric secretion and reduced acid output (Grant et al.,
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1988; Schepp et al., 1988). Additionally, rats induced via cold, restraint, and ethanol
administration had significantly reduced mucosal lesions when fed a linoleicsupplemented diet (D and A, 1991; Mandel et al., 1994; Schepp et al., 1988). Corn oil
supplementation is an economical approach to management of the equine GL mucosa,
especially when injury is caused by NSAID usage.
Gastrocure
Gastrocure is a natural feed supplement composed of Plantago ovate (Fleawort
extract), Trigonellafoenum-graecum (Fenugreek extract), Aloe Vera, and Glycyrrhiza
labra (Licorice extract). The bulk of composition is alfalfa hay, soybean kernel,
saccharose, calcium carbonate, oils and vegetable fats, magnesium hydroxide, and
methyl-sulphonyl-methane. In Italy, Stucchi Luca et al. (2017) administered Gastrocure
for 30 days to evaluate the efficacy of the product as a sole treatment option for equine
gastric ulcerations in sport horses in training. The supplement was found to be effective
in reducing gastric ulcer score and severity. Positive results may be due to various
components of the supplement, including alfalfa hay, magnesium hydroxide and calcium
carbonate, due to their buffering effects (Clark et al., 1996; Husted et al., 2008). Other
nutrients that may have had added a protective effect for the gastric mucosa include
threonine, Glycyrrhiza labra, aloe vera, antioxidant factors and mucilages. At the gastricenteric level, the amino acid threonine is involved in mucus production. Several studies
have reported the efficacy of licorice in providing anti-ulcerogenic activity by
suppressing acid secretion and increasing mucus secretion, along with promoting the
release of prostaglandin E2 (Guslandi, 1985; Kassir, 1985). Additionally, it has been
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reported that flavonoid, a content of licorice, could inhibit proton-pump activity in the
GL mucosa (Beil et al., 1995; Kassir, 1985). Due to studies on humans and rats, the antiulcerogenic capacity of aloe vera has been hypothesized due to its anti-inflammatory,
cytoprotective, and mucus-stimulating effects (Langmead et al., 2004). Antiinflammatory effects were also found in horses (Lans et al., 2006). It is further
hypothesized that aloe vera may act to increase the perfusion of gastric mucosa, which
results in vasoconstriction and promotes angiogenesis, facilitating the healing of ulcers.
Finally, mucilages which include pectin, guar, psyllium, and fenugreek in this case, form
a viscous gel when in an acidic environment, protecting the mucosa from the harsh
effects of the acidity (Ferrucci et al., 2003; Lans et al., 2006; Murray and Grady, 2002).
Polysaccharide supplement
Beta glucan
Several natural polysaccharides have been reported to have gastrointestinal
protective effects (Ding et al., 2017; Oliveira et al., 2018; Wang et al., 2018). Beta glucan
is a heterogenous polysaccharide that, as a dietary fiber, has the tendency to maintain
blood glucose and cholesterol levels and produce short chain fatty acids to promote the
growth of beneficial microflora (Guo et al., 2018; Xu et al., 2013). In rats, treatment with
soluble dietary fiber protects the GI mucosa against NSAIDs (Satoh and Urushidani,
2016). In 2019, Chen and colleagues revealed that beta glucan exerted protective effects
on the gastric mucosa by alleviating neutrophil infiltration and lipid peroxidation through
an antioxidant mechanism. Additionally, rats pretreated with beta glucan experienced a
reduced inflammatory effect after ethanol-induced gastric ulcers, indicating the effective
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inhibition of pro-inflammatory cytokines. These results elucidate the antioxidant activity
and anti-inflammatory potential of beta glucan (Chen et al., 2019).
Hericium erinaceus
In a study with rats, when comparing mucosal injury of ethanol-induced
ulceration, there are similar effects of pre-treatment omeprazole and H. erinaceus extract.
Ulcer area significantly decreased, and mucus production increased in a dose-dependent
manner in rats given varying levels of H. erinaceus extract. Rats under pre-treatment with
H. erinaceus extract showed near-normal histopathological architecture of gastric mucosa
comparable to normal rats, whereas those pre-treated with omeprazole presented with
mild inflammation and infiltration of leukocytes in the stomach. Additionally, elevated
production of reactive oxygen species (ROS) was indicated by decreased superoxide
dismutase (SOD) levels, causing gastric damage to those in the control group. Higher
doses of H. erinaceus extract caused a significant increase in SOD activity as well as
prevented a depletion in catalase (CAT) activities (Chen et al., 2019).
Administration of H. erinaceus extract has protective effects on gastric mucosa
and inhibits infiltration of leukocytes into the gastric wall in ethanol-induced gastric
ulcers. A reduction in neutrophil infiltration has been a proven marker of ulcer healing
(Shimizu et al., 2000). Leukocytes, specifically neutrophils, act as inflammatory
mediators that can release ROS that are highly cytotoxic and induce tissue damage
(Cheng and Koo, 2000). Thus, suppression of infiltration during inflammation might
hasten the rate of ulcer healing.
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The mucosal barrier plays a vital role in the protection of the gastric wall (Allen
and Flemstrom, 2005). Free mucus was significantly increased in rats pre-treated with H.
erinaceus extract in comparison with those in the ulcer control group. The mucus that
adheres to the gastric wall protects the underlying epithelium from acid, pepsin and
necrotizing agents (Alqasoumi et al., 2008).
Hyaluronan
In 2011, Al-Bayaty and colleagues performed a study to evaluate the antiulcerogenic activity of hyaluronic acid (HLA) against ethanol-induced gastric mucosal
injury in rats (Al-Bayaty et al., 2009). Many tissues’ extracellular matrix is largely
composed of HLA, a large non-sulfated glycosaminoglycan which is made up of
repeating disaccharides of D-glucuronic and N-acetyl-glucosamine (Toole, n.d.).
Fibroblasts are the primary secretors of HLA into the extracellular matrix (Mesa et al.,
n.d.). High molecular weight HLA is physiologically macro-aggregating and can perform
action against hyaluronidase, an enzyme that breaks down proteoglycans (PG) in
connective tissues and is effective at reconstructing when applied topically to damaged
barriers. In a non-disease state, PG in the mucosal connective tissue act as a barrier
against bacterial invasion and the spread of bacterial toxins.
Biochemical Analytes
Adenosine deaminase
Adenosine deaminase (ADA) is an critical enzyme involved in purine metabolism
that functions as a catalyst, allosteric modulator, and cell-cell communication molecule
(Moreno et al., 2018). There are several activities of ADA that make it a potential
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therapeutic target for disease including catalytic activity, strict control of its concentration
and its disruption of extracellular adenosine triphosphate (ATP) (Liu and Xia, 2015; Park
and Gupta, 2013).
Extracellular purines (adenosine, ATP and ADP) and pyrimidines (UDP and
UTP) are important signaling molecules that facilitate various biological processes such
as the immune response and inflammation through purine receptors (Ralevic and
Burnstock, 1998). Adenosine specifically functions as a signal to indicate tissue damage
and inflammatory changes, and can act as a stress signal by autocrine or paracrine
interactions (Camici et al., 2018; Kumar and Sharma, 2009). Adenosine can have
different effects depending on target tissue, time course (Fredholm, 2007; Linden and
Eltzschig, 2007) and receptor type, as various receptors have opposing functions
(Fredholm, 2007; Linden and Eltzschig, 2007). Adenosine deaminase acts as an
immunomodulatory and allosteric regulator by binding to adenosine receptors, and due to
opposing functions of these receptors, can elicit pro- or anti-inflammatory effects,
depending on immune status. An upregulation of ADA activity has been shown to result
in inflammation and tissue injury, while a decrease in ADA activity has been associated
with disease progression (da Silva et al., 2017; Saracoglu et al., 2005).
Total antioxidant capacity
Oxidative stress is a key element of tissue injury in gastric disease, and intestinal
insult has been directly linked to increased free radical production and a low
concentration of endogenous defense mechanisms (Grisham, 1994; Kruidenier and
Verspaget, 2002). In a study with inflammatory bowel disease patients, TAC was
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significantly reduced and was independent of disease activity and localization
(Koutroubakis et al., 2004). It is suggested that there is a relationship between serum
TAC and mucosal antioxidant activity, measuring the totality of circulating antioxidants
(Kampa et al., 2002; Malliaraki et al., 2003). Thus, it is a more accurate representation of
chronic conditions instead of acute situations. A measured decrease in TAC may be
attributable to several factors, including malabsorption and increased GI losses. A
reduction in antioxidant defense may result in the compromise of inflamed mucosa,
elevating its vulnerability to oxidative tissue damage (Koutroubakis et al., 2004).
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CHAPTER TWO
EQUINE GASTRIC ULCERS: POLYSACCHARIDE
SUPPLEMENTTION AS A SOLUTION
Introduction
The term “Equine Gastric Ulcer Syndrome” (EGUS) encompasses several
disorders of the stomach and can be further defined by location. Distinguishing between
Equine Squamous Gastric Disease (ESGD) and Equine Glandular Gastric Disease
(EGGD) is imperative, as their pathophysiology and treatment needs vary. Hydrochloric
acid (HCl) exposure, volatile fatty acid (VFA) injury, and the synergistic effect of bile
acid and bacterial fermentation byproduct of non-structural carbohydrates (NSC) with
HCl are major offenders of the squamous (SQ) mucosa. Successful injury resolution of
SQ mucosa is widely achieved by the suppression of gastric acid. Pathophysiology of
glandular (GL) mucosa is less well understood, but it is potential that nonsteroidal
inflammatory drugs (NSAIDs) and bacteria play a role in the development of ulcers in
this region. It has been found that GL ulcers require longer treatment duration than SQ
ulcers, thus acid suppression coupled with therapies such as antimicrobials and mucosal
coating agents show promise for efficient healing of the GL mucosa.
Omeprazole, a proton pump inhibitor (PPI), is the most common acid suppression
therapy administered to horses suffering from ESGD and EGGD. It results in varying
healing rates of the SQ and GL mucosa, is costly, and is not viable for long-term
administration. The use of nutraceuticals and natural, long-term supplements are
becoming a more appealing opportunity to the industry. Several options with varying
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rates of efficacy are available including pectin-lecithin complexes, magnesium
hydroxide, and sea buckthorn berries to name a few. More conclusively, high molecular
weight hyaluronan (HA) has been proven to protect gastric mucosa from injury (AlBayaty et al., 2009), and beta glucan supports enhanced gastroprotection and contains
bioactive components with anti-ulcer activities (Wong et al., 2013). The goal of this
research was to quantify the effect of a natural supplement containing HA and beta
glucan, further referred to as “polysaccharide supplement” (PS), on SQ and GL ulcers in
the equine stomach.
Materials and Methods
This research was approved by the Institutional Animal Care and Use Committee
of Clemson University (AUP #2020-013).
Induction
Gastric ulcers were induced in horses using a modified Murray method before
onset of the 6-week supplemental period. Horses alternated four 12-hour periods of feed
deprivation and normal feeding routine as well as two 24-hour feed deprivations leading
up to the initial endoscopy (Day 0), for a total of 108 hours of feed deprivation. After
ulcers were induced, horses underwent an initial pre-screening endoscopy (Day 0) to
determine the extent of gastric ulcer presence in the SQ and GL regions of the stomach.
These results were assessed, and scores of SQ and GL ulcerations were assigned. Prior to
the other two examinations (Days 21 and 42), horses were fasted for 16 hours and water
withheld for a minimum of three hours to ensure visibility during the procedure.

28

Endoscopy
Endoscopic examinations were performed with a 3m long equine gastroscope by
the same board-certified veterinarian on days 0, 21, and 42. Preparation for endoscopies
included feed and water restrictions, as well as sedation. Once sedated, horses were
secured in stocks prior to the beginning of the procedure. Before alterations to the gastric
environment were made, stomach fluid samples from the proximal and distal regions
were aspirated via 60mL syringe through the biopsy channel. During the endoscopic
procedure, the stomach was distended by the insufflation of air until the SQ and GL
regions were visible, then gastric contents were rinsed from the stomach surface using
distilled water flushed through the biopsy channel. At the conclusion of the procedure the
stomach was desufflated, the endoscope was withdrawn, and horses were recovered from
sedation.
Ulcer grading
During the endoscopic examination, images were captured and digitized with a
portable personal computer. Images of irritation, thickening of the mucosa, ulcers, and
other abnormalities were captured. Location of the ulcers indicated further whether the
horses had ESGD or EGGD. Lesion scores, assigned blindly by the veterinarian, ranged
from 0-4 for each of the ulcer types (Table 1; (Sykes and Jokisalo, 2014, p. 1).
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Table 1: Grading system for the squamous and glandular mucosa
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4

Squamous mucosa
The epithelium is intact
and there is no appearance
of hyperkeratosis
The mucosa is intact but
there are areas of
hyperkeratosis
Small, single, or multifocal
(< 5) superficial lesions
Large, single deep or
multiple (≥ 5) focal
superficial lesions
Extensive lesions with
areas of apparent deep
ulceration

Glandular mucosa
The epithelium is intact
and there is no evidence of
hyperemia
The mucosa is intact but
there are areas of
hyperemia
Small, single, or multifocal
(< 5) superficial lesions
Large, single deep or
multiple (≥ 5) focal
superficial lesions
Extensive lesions with
areas of apparent deep
ulceration

Experimental design
Eight mature geldings (Quarter Horse, Thoroughbred) were match-paired
according to ulcer grade following the pre-screening endoscopy (Day 0). Horses ranged
from 10 to 20 years in age and 534 to 643kg in body weight (BW) and were randomly
assigned to one of two groups; treatment (TRT; n=4) or control (CTRL; n=4). The TRT
horses received 1oz PS supplement top-dressed on their concentrate meals at 0600 and
1800hrs daily for 6 weeks. The experiment was divided into three periods: presupplementation (D 0), mid-supplementation (D 28), and post-supplementation (D 42).
During each period, endoscopies were performed and stomach fluid samples were
collected.
Diet
All horses were fed to meet or exceed the NRC suggested nutrient requirements
for horses at maintenance (NRC, 2007). Daily diets consisted of fescue hay (Festuca
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pratensis) fed at a rate of 1.0% BW (as-fed) and a commercial concentrate (Nutrena®
Triumph® Fiber Plus, Cargill®, Inc., Holmesville, OH) fed at a rate of 0.25% BW (asfed). Daily diets were separated into two meals fed at 0600 and 1800. Polysaccharide
treatment (1oz) was fed to TRT horses at each meal. Composition of the supplement
included purified water, liquid Aspergillus oryzae fermentation product, H. erinaceus
(lion’s mane) extract, hyaluronan, sodium chloride, xanthan gum, citric acid, potassium
sorbate and sodium benzoate (BioZyme®, Inc., St. Joseph, MO). There were no refusals
of diet or treatment. Two 0.809ha pastures (PAS; n=4 horses per pasture) composed of
fescue (Fescue pratensis), clover (Trifolium repens), annual rye (Lolium multiflorum) and
other native grasses were utilized. Water was provided ad libitum.
Management of horses
All horses were weighed weekly with feed amounts adjusted accordingly. Horses
were housed in 3.05x3.65m stalls and turned out into PAS from 0600-1800hrs and 18000600hrs, respectively.
After conclusion of the 6-week supplementation period, horses with remaining
ulcerations upon final endoscopy (D 42) underwent oral omeprazole treatment based on
severity. Those with scores 0-1 in the SQ and/or GL region were exempt from treatment.
Those with scores of 2 or higher in the SQ region, GL region or both received a full dose
of GastrogardÒ once daily on an empty stomach for 2 weeks. This was followed by a half
dose or a 500lb dose, once daily for 2 weeks. Finally, the horses underwent a 250lb dose
once daily for 2 weeks. Horses that underwent GastrogardÒ treatment were subject to an
additional endoscopy after 2 weeks of treatment in order to assess efficacy (D 76).
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Statistical analyses
The effects of date and treatment were analyzed with a factorial ANOVA. All
statistical calculations were performed using the software JMP.
Results
Ulcer scores
There was no difference between mean ulcer scores of TRT and CTRL groups
across time (Figure 2.1; P=0.776). However, over the course of the 6-week supplemental
period, all horses’ pooled SQ and GL ulcer scores decreased (Figure 2.2; P=0.001).
While the overall main effect of ulcer scores between SQ and GL regions did not differ,
at day 42 it was noted that SQ tissue presented with higher ulcer scores than GL (Figure
2.3; P=0.006). Further, between TRT and CTRL horses, no difference was seen between
SQ and GL ulcer scores across time (2.4a-b; P=0.145, 0.859 and 0.437 for day 0, 21 and
42, respectively.
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Figure 2.1: Gastric ulcer scores on day 0, 21 and 42 of polysaccharide supplemented
(TRT; n=4) versus non-supplemented horses (CTRL; n=4)

A Days with different letters are significantly different

Figure 2.2: Gastric ulcer scores on day 0, 21 and 42 of all experimental horses (n=8)

AB Days with different letters are significantly different
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Figure 2.3: Squamous (SQ) versus glandular (GL) gastric ulcer scores on day 0, 21 and
42 of all experimental horses (n=8)

*Indicates significant differences in squamous tissue ulcer scores compared to glandular
tissue ulcer scores on a specific day

Figure 2.4a: Squamous (SQ) gastric ulcer scores on day 0, 21 and 42 of polysaccharide
supplemented horses (TRT; n=4) versus non-supplemented horses (CTRL; n=4)

Main effect P > 0.05
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Figure 2.4b: Glandular (GL) gastric ulcer scores on day 0, 21 and 42 of polysaccharide
supplemented horses (TRT; n=4) versus non-supplemented horses (CTRL; n=4)

Main effect P > 0.05
Further statistical analyses were completed with the inclusion of a block for ulcer
location (UL). In the SQ region, UL were defined as: 1 = near the margo plicatus (MP)
and 2 = other than near the MP. In the GL region, UL were defined as: 3 = in the pyloric
(P) region and 4 = other than in the P region. A difference was seen among all UL for
both TRT and CTRL groups across time (Figure 2.5; P=0.0463). Despite these time
differences, there was no overall difference between the SQ and GL regions of the TRT
and CTRL groups (P=0.5448).
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Figure 2.5: Ulcer scores in various areas (margo plicatus (MP), non-margo plicatus
(NMP), pylorus (P) and non-pylorus (NP)) on day 0, 21 and 42 of all experimental horses
(n=8)

AB Ulcer location across days 0, 21 and 42 with different letters differ statistically (P<
0.05)
Main effect P<0.01
Gastric pH
There was no difference in proximal or distal pH between TRT and CTRL groups
across time (P=0.487). As expected, there was a difference between the pH values in the
proximal and distal portions of the stomach across all horses (Figure 2.6; P=0.014).
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Figure 2.6: pH values of the proximal and distal regions of the equine stomach on day 0,
21 and 42 of all experimental horses (n=8)

Main effect P=0.0143
Discussion
The severity of ulcer scores in all experimental horses indicated that the modified
Murray induction method was adequate to test the hypothesis and to induce lesions to the
gastric mucosa. While there was no difference between mean ulcer scores of TRT and
CTRL groups, there was an overall decrease in the horses’ pooled SQ and GL ulcer
scores over the course of the 6-week supplemental period. This lack of difference may be
attributable to the horses’ inactivity, as it has been shown that there is a strong
relationship between exercise intensity and duration with prevalence, severity and
number of lesion sites (Murray et al., 1996; Roy et al., 2005; Orsini et al., 2009).
Moreover, the supplementation of polysaccharide therapy may have shown a lack of
effect due to the provoked condition of the gastric mucosa and may instead be effective
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in maintaining mucosa of horses with naturally occurring ulcers. In another study
concerning the effect of polysaccharides on equine gastric ulcers, supplementation was
found to resolve or improve 90% of ulcerations in adult horses in active training (Slovis,
2017). Additionally, adeptness of the mucosa to naturally heal should be considered, as
CTRL horses had an improvement of 44% overall ulcer score, 17% SQ score, and 70%
GL score over the 6-week supplemental period. There are several factors that may have
aided in the natural healing process, the first being constant access to forage in the form
of hay or pasture. In 2015, Sykes and colleagues highlighted the reduced risk of
ulceration alongside free access or frequent feeding of fibrous roughage. Further, horses
were fed minimal percentage of their BW in concentrates, thus non-structural
carbohydrates, as recommended by the NRC. Since it has been shown that starch intake
increases the likelihood of gastric ulceration, it is possible that the minimal offering of
concentrates further contributed to the high natural healing rates (Luthersson et al.,
2009b).
No difference was found between the SQ and GL ulcer scores of all horses until
day 42, where SQ ulcer scores were markedly higher than GL ulcer scores. This aligns
with recent literature which found there is no relationship between ESGD and EGGD in
the sense that one cannot be used as a predictor for the presence or absence of the other
(Sykes et al., 2015a). Additionally, there was no difference of SQ and GL ulcer scores
between TRT and CTRL groups. Given the differences in pathogenesis, prevalence and
risk factors, it might be that after sufficient time, supplementation could potentially affect
the SQ and GL mucosa differently. Differing treatment recommendations for SQ and GL
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ulcers is a novel concept. Investigation on this subject is warranted as remarkable
differences in healing rates have been recorded between SQ and GL ulcers with
omeprazole treatment regarding duration of acid suppression, duration of treatment, and
use of adjunctive therapies (Sykes et al., 2015a). Typically, GL ulcers require longer
treatment duration than SQ ulcers, and treatment methods are targeted towards resolving
the breakdown of natural barriers as opposed to reducing exposure to acidic injury. The
SQ tissue can benefit from limiting contact of acidic gastric contents in order for
intercellular tight junctions and intracellular buffering systems to regain function, and GL
tissue has an opportunity to heal when coating agents form a pseudomucus layer,
allowing for the tissue to regenerate the integrity of the mucosal layer. Pharmaceuticals
and nutraceuticals can collaborate to create the most conducive environment for gastric
healing. While acid suppression is currently the cornerstone for treatment of both SQ and
GL tissues, the role of the efficacy of adding adjunctive therapies should not be
dismissed.
Within the SQ and GL mucosa, there are areas that appear to be more prone to
irritation and ulceration. The area surrounding the margo plicatus (MP) is a common
lesion site in the SQ portion of the stomach, while the pyloric region (P) is where GL
lesions are most commonly found. In the current study, of the SQ ulcerations observed,
61% were present around the MP while 65% of GL ulcerations were in the P region. A
difference was seen among ulcer locations (UL) for both TRT and CTRL groups across
time. As of late, histopathological findings are being used in an attempt to differentiate
pathogeneses of disease of various regions of the equine stomach. The SQ tissue reacts to
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excessive exposure to acidic gastric contents by thickening and becoming hyperkeratotic,
which eventually results in the sloughing of the superficial layers of the mucosa. This
leads to vulnerability of the mucosa to opportunistic bacteria, followed by the localized
migration of inflammatory cells. The lesion will deepen, allowing for progression to
ulceration, which fully exposes the tissue to acidic contents of the stomach (Martineau et
al., 2009). This sequence of events occurs most commonly at the MP because it is the
most vulnerable region of SQ tissue due to anatomical configuration of the equine
stomach and its role as the intersection between the two tissue types. Thus, it is more
prone to exposure to acidic gastric contents and does not possess the protective properties
present in the GL mucosa. The process of spontaneous GL tissue ulceration is less
understood. Excessive acid exposure does not seem to be a primary factor and studies
speculating the harboring of an equine specific Helicobacter-like organism have yielded
inconsistent results (Blikslager et al., 2017). Mucosal injury via refluxed bile acids should
be considered, as this is a common occurrence in horses and can result in irritation to the
mucosa. Interestingly, adaptive protection of the GL mucosa from the irritating effects of
bile acids has been previously described, as injury typically occurs only when mucosal
protective processes are impaired (Murray et al., 2001).
Though there were no differences of pH between the TRT and CTRL groups,
there was a difference between the proximal and distal regions’ pH levels across all
horses. Consistently, it was found that distal pH was lower than proximal pH. Literature
supports that the pH in the distal region of the stomach is relatively stable around 3,
which aligns with findings of the current study (Sykes and Jokisalo, 2015, p. 3). Proximal
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pH did not drop below 4, so the presence of ulcers is contradictory to literature defining
this threshold as ulcerogenic for SQ tissue (Husted et al., 2009). This difference may be
due to the lack of an induction in horses in the aforementioned study.
Conclusion
Polysaccharide supplementation at 1oz twice per day over a 6-week period did not
have an effect on ulcer scores in the SQ or GL region. A significant recovery was seen by
all experimental horses following the induction of gastric ulcers. The endoscopy on day
42 revealed elevated SQ ulcer scores, supporting that healing rates of SQ and GL tissue
are independent of each other. Additionally, the polysaccharide supplement did not
influence pH values and all horses exhibited higher proximal than distal pH. The lack of
effect may be due to conditions of induced ulcers, as studies involving naturally
occurring ulcers have shown a more positive healing effect from polysaccharide
supplementation. It may be beneficial to evaluate the efficacy of polysaccharide
supplementation in horses that are active in training with naturally occurring ulcers.
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CHAPTER THREE
EQUINE GASTRIC ULCERS: ASSOCIATED BIOMARKERS
Introduction
The prevalence of EGUS varies with breed, use, level of training, as well as
between ESGD and EGGD (Sykes and Jokisalo, 2015). Up to 90% of performance horses
are affected by gastric ulcers. Individual cases vary with clinical signs including reduced
appetite, poor body condition, behavioral inconsistencies, and reduced performance,
among others. There are many risk factors, with exercise and diet being the most
influential. Currently, the only reliable antemortem diagnostic method for EGUS is
endoscopy. This procedure involves feed and water restriction, as well as sedation.
Though it is definitive, the process of endoscopy is cost-prohibitive and is not
accommodating to the equine stomach. As fasting is a risk factor for the development of
ulcers, it seems counterintuitive to require it for diagnosis. The development of a salivary
or serum panel for aid in the diagnostics of EGUS would provide a much less expensive
and invasive method of determining gastric integrity.
Saliva, which is composed of 99% water, contains other compounds, hormones,
and enzymes that have potential for aiding in diagnostics of systemic disorders. Saliva
poses some advantages over blood collection, as it is non-invasive, non-stressful, and can
be performed by those without training. Salivary analytes have been assessed in several
species, including swine and equine, and usually revolve around markers indicative of
stress response. There are minimal studies evaluating panels of analytes associated with
Equine Gastric Ulcer Syndrome (EGUS). An exploratory study followed up with a
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confirmatory study in 2019 found several analytes that were elevated in horses with acute
abdominal disease and also correlated with their respective serum concentrations
(Contreras-Aguilar et al., 2019).
Though it is more invasive than saliva collection, blood collection for serum
analysis is markedly less invasive and expensive than an endoscopic procedure, and the
process can be taught with minimal training. Various biochemical markers are useful for
measuring values such as oxidative stress, pathologic conditions, and immune response
(Bagheri et al., 2019; Beyazit et al., 2012).
The goal of this research was to establish a relationship between salivary and
serum analytes with gastric ulcer scores of the SQ and GL region of the equine stomach
in order to potentiate a less-invasive diagnostic technique for EGUS.
Materials and Methods
This research was approved by the Institutional Animal Care and Use Committee
of Clemson University (AUP #2020-013).
Experimental design
Eight mature geldings (Quarter Horse, Thoroughbred) were match-paired
according to ulcer grade following the pre-screening endoscopy (Day 0). Horses ranged
from 10 to 20 years in age and 534 to 643kg in body weight (BW) and were randomly
assigned to one of two groups; treatment (TRT; n=4) or control (CTRL; n=4). The TRT
horses received 1oz PS supplement top-dressed on their concentrate meals at 0600 and
1800hrs daily for 6 weeks. The experiment was divided into three periods: presupplementation (D 0), mid-supplementation (D 28), and post-supplementation (D 42).
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During each period, endoscopies were performed and stomach fluid samples were
collected.
Diet
All horses were fed to meet or exceed the NRC suggested nutrient requirements
for horses at maintenance (NRC, 2007). Daily diets consisted of fescue hay (Festuca
pratensis) fed at a rate of 1.0% BW (as-fed) and a commercial concentrate (Nutrena®
Triumph® Fiber Plus, Cargill®, Inc., Holmesville, OH) fed at a rate of 0.25% BW (asfed). Daily diets were separated into two meals fed at 0600 and 1800. Polysaccharide
treatment (1oz) was fed to TRT horses at each meal. Composition of the supplement
included purified water, liquid Aspergillus oryzae fermentation product, H. erinaceus
(lion’s mane) extract, hyaluronan, sodium chloride, xanthan gum, citric acid, potassium
sorbate and sodium benzoate (BioZyme®, Inc., St. Joseph, MO). There were no refusals
of diet or treatment. Two 0.809ha pastures (PAS; n=4 horses per pasture) composed of
fescue (Fescue pratensis), clover (Trifolium repens), annual rye (Lolium multiflorum) and
other native grasses were utilized. Water was provided ad libitum.
Management of horses
All horses were weighed weekly with feed amounts adjusted accordingly. Horses
were housed in 3.05x3.65m stalls and turned out into PAS from 0600-1800hrs and 18000600hrs, respectively.
After conclusion of the 6-week supplementation period, horses with remaining
ulcerations upon final endoscopy (D 42) underwent oral omeprazole treatment based on
severity. Those with scores 0-1 in the SQ and/or GL region were exempt from treatment.
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Those with scores of 2 or higher in the SQ region, GL region or both received a full dose
of GastrogardÒ once daily on an empty stomach for 2 weeks. This was followed by a half
dose or a 500lb dose, once daily for 2 weeks. Finally, the horses underwent a 250lb dose
once daily for 2 weeks. Horses that underwent GastrogardÒ treatment were subject to an
additional endoscopy after 2 weeks of treatment in order to assess efficacy (D 76).
Biological sampling
During each period, samples of saliva and blood were collected prior to
endoscopic procedure. Though horses were in a fasted state, the mouth was rinsed of any
remaining feedstuffs as a precautionary measure to avoid contamination. Saliva
collection was performed by insertion of a 6.0x10-4m2 compressed sponge (Arcliber®
cellulose sponge) through the bars of each horse’s mouth to be chewed until saturated
with saliva. The procedure lasted approximately 90 seconds. Then, sponges were placed
into salivette tubes after removal of the included cotton swab (Salivette Tubes, Fisher
Scientific®) and were stored in a cooler until transport to Clemson University within the
same day to be centrifuged at 3200rpm for 15 minutes. Following this, all were aliquoted
into appropriately labeled microcentrifuge tubes (Eppendorf™ Tubes, Fisher Scientific®)
and stored at -80°C.
Blood samples were collected by jugular venipuncture into Vacutainer® rapid
serum test (RST) tubes via a double-ended bleeding needle (BD Vacutainer® Rapid
Serum Tubes, Mississauga, ON). Blood samples were stored in a cooler until transport to
Clemson University within the same day to be centrifuged at 1300rpm for 15 minutes.
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Following this, all were aliquoted into appropriately labeled microcentrifuge tubes
(Eppendorf™ Tubes, Fisher Scientific®) and stored at -80°C.
Biochemical analyses
Adenosine deaminase
The salivary and serum levels of ADA activity were quantified using an
optimized adaptation of a commercial automatized assay (BioSystems S.A.; Gutiérrez et
al., 2017). The method of the assay is based on the measurement of the decrease in
absorbance (OD) per minute of a coupled reaction initially catalyzed by ADA. The
reaction is measured at 340nm. The levels of ADA activity were calculated according to
the manufacturer’s instructions (ΔOD/min x 3333 = U/L). The optimal sample dilutions
were 1:8 for saliva and 1:4 for serum samples.
Cortisol and alpha amylase
The cortisol content in the salivary samples were measured using an optimized
commercial competitive ELISA assay (Extended range high sensitivity salivary cortisol
Enzyme immunoassay kit, Salimetrics, USA). No dilution of horse saliva was applied
under the optimal conditions of the assay. Cortisol levels were calculated according to the
manufacturer’s instructions (3 𝛍g/dL = 82.77 nmol/L).
Total antioxidant capacity
The TAC was measured in the saliva and serum samples by the ferric reducing
antioxidant power assay, which was optimized for the two-horse body-fluids (Benzi et
al., 1996). The method consisted in the reduction of the ferric complex tripiridil triazine
(Fe3+ TPTZ) to form Fe2+ in an acidic medium. Prior to its implementation, the optimal
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sample dilution was calculated using a standard curve of Trolox (a water-soluble analog
of vitamin E employed as a control antioxidant agent for assay calibration), ranging from
1.5 to 100 μM Trolox equivalents. No sample dilution was required.
Total protein
The total protein content of serum and saliva samples was determined according
to standard protocols (Bradford, 1976). A calibration curve with five standards based on
bovine serum albumin was used with a concentration range of 5-100 ng/mL. For serum
determinations, a sample dilution of 1:1000 was used while for saliva the optimal dilution
for analysis was 1:20.
Immunoglobulin levels
For the quantifications of serum IgG levels, serum samples were diluted at
1:200000 for proper measurements using a commercial ELISA assay (IgG Horse ELISA
kit, Abnova) according to the manufacturer’s instructions. The amount of salivary IgA
was measured using an optimized commercial ELISA assay (IgA Horse ELISA kit,
Abnova) with a saliva dilution of 1:5000.
Results
Biochemical analytes
Salivary analytes
There was no correlation between salivary total protein (TP), cortisol (CORT),
and immunoglobulin A (IgA) concentrations and ulcer scores in the SQ or GL regions of
the TRT or CTRL group. However, TRT horses’ adenosine deaminase (ADA)
concentrations had a tendency to correlate with ulcer scores in the GL region (Figure 3.1;
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P=0.061; R2=0.308). In the CTRL group, there was a negative correlation between total
antioxidant capacity (TAC) and GL ulcer scores (Figure 3.2; P=0.051; R2=0.330).

Figure 3.1: Salivary adenosine deaminase (ADA) concentrations from day 0, 21 and 42
sample collections in polysaccharide supplemented (TRT; n=4) and non-supplemented
horses (CTRL; n=4) with glandular (GL) ulcers

*Indicates trend for linear significance (P=0.061)
Linear y = -0.0004x + 4.5387
R² = 0.308
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Figure 3.2: Salivary total antioxidant capacity (TAC) concentrations in polysaccharide
supplemented (TRT; n=4) and non-supplemented horses (CTRL; n=4) with glandular
(GL) ulcers

*Indicates significant linear trend (P=0.051)
y = -0.0604x + 3.3768
R² = 0.330
Serum analytes
There was no correlation between serum ADA or TP concentrations with SQ
ulcer scores of the TRT or CTRL group, nor any correlation between serum TAC
concentration in the TRT group. There was no correlation between serum ADA
concentration in the CTRL group, TAC in both groups nor TP concentration in the TRT
group with GL ulcer scores. However, there was a strong positive correlation found
between serum TAC and SQ scores in the CTRL group (Figure 3.3; P=0.002; R2=0.620).
In the TRT group, a positive correlation was found for serum ADA and GL ulcer scores
(Figure 3.4; P=0.028; R2=0.399). In the CTRL group, a negative correlation was found
between GL ulcer score and serum TP levels (Figure 3.5; P=0.016; R2=0.456).
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Figure 3.3: Serum total antioxidant capacity (TAC) levels in polysaccharide
supplemented (TRT; n=4) and non-supplemented horses (CTRL; n=4) with squamous
(SQ) ulcers

*Indicates significant linear trend (P=0.002)
y = 0.2952x - 3.717
R² = 0.62
Figure 3.4: Serum adenosine deaminase (ADA) levels in polysaccharide supplemented
(TRT; n=4) and non-supplemented horses (CTRL; n=4) with glandular (GL) ulcers

*Indicates significant linear trend (P=0.028)
y = 0.0199x - 3.1444
R² = 0.3987
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Figure 3.5: Serum total protein (TP) levels in polysaccharide supplemented (TRT; n=4)
and non-supplemented horses (CTRL; n=4) with glandular (GL) ulcers

*Indicates significant linear trend (P=0.016)
y = -0.0553x + 6.2617
R² = 0.456
Discussion
A negative correlation was found between salivary adenosine deaminase (ADA)
and GL ulcer scores of the TRT group, meaning ADA concentrations were increased in
TRT horses with lower GL ulcer scores. This contradicts findings in studies observing
salivary analytes in swine, in which ADA concentrations were increased by acute stress
or pathologic conditions (Contreras-Aguilar et al., 2019; Tecles et al., 2018, 2017).
However, it has been found that ADA can have either pro- or anti-inflammatory effects,
depending on immune status, due to differences in response to various receptors. It is
possible that levels of ADA are increased in horses with lower GL scores due to working
as an anti-inflammatory agent. There are cases in humans in which decreased ADA
concentrations are associated with the progression of disease, such as in some cancers.
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This is most likely by mechanism of neutralizing the upregulated purine and DNA
metabolism, and the effects on tissues will depend on the length of time that has passed
from the initial injury (Bagheri et al., 2019).
Salivary total antioxidant capacity (TAC) concentrations had a negative
correlation with the GL scores of the horses in the TRT group. The negative correlation is
especially unprecedented in the TRT group, as the particular polysaccharide in the
supplement has been shown to reduce free radicals in the body, acting as an antioxidant
(Brindzova et al., 2008). This contradictory result may be due to the salivary sampling
method, or the use of a low of a molecular weight beta-glucan (Błaszczyk et al., 2015).
A positive correlation was present between serum TAC concentrations and SQ
ulcer scores in the CTRL group. The involvement of free radicals is known to be
involved in the genesis of gastric ulcers as well as other malignancies of the GI tract
(Tandon et al., 2004). Free radical accumulation is modulated by antioxidant enzymes,
and when these factors are imbalanced the reactive oxygen species (ROS) cause tissue
damage.
Serum ADA levels correlated positively with GL ulcer scores of TRT horses such
that as ADA concentrations increased, the GL ulcer scores did as well. ADA
concentration increases with various diseases, which may be due to its macrophage and
monocyte lineage, reflecting the immune response (Bagheri et al., 2019). In humans with
GI disease, serum ADA levels were elevated, suggesting a fractional role of activated Tcell response in the disease pathophysiology (Beyazit et al., 2012). Increased ADA
activity was detected in the GI tract of rats following inflammatory insult of the
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gastrointestinal (GI) tract. Catabolic degradation of adenosine by ADA may result in
impairment of immune modulation by adenosine, resulting in the worsening of
inflammation and tissue injury (Antonioli et al., n.d.; Vieira et al., 2014). Adenosine has
the potential to mediate pro-inflammatory and/or anti-inflammatory and
immunosuppressant activities in gut diseases in humans and rats, but more research is
needed to assess the efficacy of this therapy in equine GI disease.
Conclusion
Specific salivary and serum analytes correlated variously with ulcers in the SQ
and GL regions of the equine stomach. Of the salivary analytes, ADA and TAC showed
relationships with ulcer scores. The GL ulcer scores of the TRT group correlated
negatively with salivary ADA concentrations, potentially due to the effect of time from
initial tissue injury. Additionally, the GL scores of the TRT group correlated negatively
with salivary TAC concentrations, possibly due to the oxidative stress occurring in the
damaged tissue. Of the serum analytes, ADA, TAC and TP showed relationships with
ulcer scores. The GL scores of the TRT group correlated positively with serum ADA
concentrations, likely due to an immune and inflammatory response. The SQ scores of
the CTRL group correlated positively with serum TAC concentrations, posing an
unexpected relationship that may be due to acute rather than chronic ulcerations. The GL
scores of the CTRL group correlated negatively with serum TP concentrations,
potentially due to low hydration levels of horses post-fasting and water withdrawal.
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CHAPTER FOUR
SUMMARY
The results of this study indicate that polysaccharide supplementation at 1oz twice
daily over a 6-week period does not have an effect on ulcer scores in the SQ or GL region
of the equine stomach in a fasting-induced model. It is possible that the induced model is
not the most proficient way of assessing the efficacy of the supplement as both the TRT
and CTRL groups healed at the same rate over the 6-week period. In addition, the lack of
common risk factors such as intermittent forage availability, exercise, and transportation
may have contributed to high natural healing rates. The inconsistent improvement of
scores between the SQ and GL ulcers further supports the novel concept of tailoring
treatment to the region of ulceration, as the pathophysiology and healing rates of the two
tissue types differ greatly. Further, predisposition of common areas to ulceration due to
anatomical configuration of the stomach is an important factor to consider for treatment.
Consistent with literature, there was an average ventral pH of around 3. Due to the
horses’ fasted state, cardiac pH averaged around 4, though under normal conditions it is
typically around 7. As the ulcerogenic threshold for SQ ulceration has been defined at a
pH of 4, exploration of diagnostic or screening methods outside of endoscopies should be
pursued due to the procedure’s required fasting.
There were correlations of several salivary and serum analytes with ulcerations of
various regions in the equine stomach. Of the salivary analytes, ADA and TAC showed
relationships with ulcer scores. The GL ulcer scores of the TRT group correlated
negatively with salivary ADA concentrations, potentially due to the effect of time from
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initial tissue injury. Additionally, the GL scores of the TRT group correlated negatively
with salivary TAC concentrations, possibly due to the oxidative stress occurring in the
damaged tissue. Of the serum analytes, ADA, TAC and TP showed relationships with
ulcer scores. The GL scores of the TRT group correlated positively with serum ADA
concentrations, likely due to an immune and inflammatory response. The SQ scores of
the CTRL group correlated positively with serum TAC concentrations, posing an
unexpected relationship that may be due to acute rather than chronic ulcerations. The GL
scores of the CTRL group correlated negatively with serum TP concentrations,
potentially due to low hydration levels of horses post-fasting and water withdrawal.
The data represented in this study provide a valuable basis for the continued
pursuit of knowledge concerning the efficacy of polysaccharide supplementation on
naturally occurring ulcers, as well as developing a less invasive diagnostic or screening
technique for detecting equine gastric ulcers. Additional research involving a noninduced model and non-fasted collection of biological samples may further define the
effect of polysaccharide supplementation on equine gastric ulcers and provide a more
accurate representation of the horse’s biochemical status.
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